IP Library Granted Patent US 9,120,031
Granted Patent B2
US 9,120,031 · App. 11/458,008 · Granted Sep 1, 2015

Compositions of particulate coformulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,120,031
App. No.
11/458,008
Granted
Sep 1, 2015
Kind
B2
Abstract

Embodiments of the invention provide a composition of a particulate coformulation which includes particles containing an active substance and an additive, wherein each particle contains a relative additive concentration increasing radially outwards from a particle center to a particle surface along a finite gradient. In one example, the particle surface is an additive-rich surface without a distinct physical boundary between the particle center and the particle surface. The relative additive concentration may have a continuous rate of change across the finite gradient. In some examples, an active substance: additive ratio of the particle surface is sufficiently low to form a protective surface layer around the active substance. Generally, the particle surface is free of the active substance.

Claims (20)

1. A composition of a particulate coformulation, comprising:

particles comprising a solid dispersion of an active substance and an additive throughout each particle of the particulate coformulation, wherein each particle comprises:

a particle surface having a surface concentration within a range from about 0% to about 10% by weight of the active substance;

a particle core having a central region concentration within a range from about 90% to about 100% by weight of the active substance; and

an additive concentration increasing radially outwards through the particle core to the particle surface along a finite gradient, wherein each particle lacks a distinct physical boundary between the particle core to the particle surface, is spherical or substantially spherical, and has a volume mean diameter within a range from about 0.5 μm to about 100 μm, wherein the active substance is in crystalline form and the additive is in amorphous form.

2. A composition of a particulate coformulation, comprising:

particles comprising a solid dispersion of an active substance and an additive throughout each particle of the particulate coformulation, wherein each particle comprises:

a particle core having a central region concentration within a range from about 90% to about 100% by weight of the active substance;

a particle surface having a surface concentration within a range from about 0% to about 5% by weight of the active substance; and

an additive concentration increasing radially outwards through the particle core to the particle surface along a finite gradient, wherein each particle lacks a distinct physical boundary between the particle core to the particle surface, wherein the particulate coformulation is or comprises a pharmaceutical agent or a nutraceutical agent, wherein the active substance is in crystalline form and the additive is in amorphous form.

3. A composition of a particulate coformulation, comprising:

particles comprising a solid dispersion of an active substance and an additive throughout each particle of the particulate coformulation, wherein each particle comprises:

a particle core having a central region concentration within a range from about 80% to about 100% by weight of the active substance;

a particle surface having a surface concentration within a range from about 0% to about 10% by weight of the active substance; and

an additive concentration increasing radially outwards through the particle core to the particle surface along a finite gradient, wherein each particle lacks a distinct physical boundary between the particle core to the particle surface, wherein both the active substance and the additive comprise different pharmaceutically active substances for co-administration.

4. A composition of a particulate coformulation, comprising:

particles comprising a solid dispersion of an active substance and an additive throughout each particle of the particulate coformulation, wherein each particle comprises:

a particle core having a central region concentration within a range from about 80% to about 100% by weight of the active substance;

a particle surface having a surface concentration within a range from about 0% to about 10% by weight of the active substance; and

an additive concentration increasing radially outwards through the particle core to the particle surface along a finite gradient, wherein each particle lacks a distinct physical boundary between the particle core to the particle surface, wherein the active substance is in crystalline form and the additive is in amorphous form.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 28571, FRAME 0141 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036866/0700 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
GRANT OF SECURITY INTEREST Recorded Jul 17, 2012
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 028571/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2012
From: NEKTAR THERAPEUTICS UK, LTD.
To: NEKTAR THERAPEUTICS
Reel/Frame 027912/0052 →